Related Experiment Video
Updated: Jul 6, 2026
07:42
Laser-capture Microdissection of Human Prostatic Epithelium for RNA Analysis
Published on: November 26, 2015
Expression profiling of CD133+ and CD133- epithelial cells from human prostate
Christopher J Shepherd1, Siân Rizzo, Ioanna Ledaki
1Prostate Stem Cell Laboratory, Institute of Cancer Research, Sutton, Surrey, UK.
The Prostate
|April 10, 2008
Summary
Researchers profiled CD133-expressing prostate cells, identifying distinct molecular signatures for stem/progenitor and transit amplifying populations. This research offers insights into prostate cancer
Area of Science:
- Prostate stem cell biology
- Cancer cell characterization
- Molecular profiling
Background:
- Prostate stem cells in benign and tumor tissues express CD133.
- Characterization of these CD133-expressing cells is limited.
- Gene expression profiling of CD133+ cells is needed.
Purpose of the Study:
- To perform gene expression profiling of CD133-expressing prostate cells.
- To characterize CD133+ and CD133- cell populations from benign and hormone-refractory prostate cancer (HRPC) tissues.
- To identify potential therapeutic targets in prostate cancer.
Main Methods:
- Analysis of CD133-positive (CD133+) and CD133-negative (CD133-) epithelial cell subpopulations.
- Isolation of cells from benign human prostate tissue and HRPC.
- Gene expression profiling and protein expression analysis.
Main Results:
- CD133+ cells from benign tissue showed stem/progenitor cell characteristics.
- CD133- cells exhibited a transit amplifying cell profile with high proliferation and metabolism.
- HRPC-derived CD133+ cells displayed tumor-specific patterns, including increased metabolic activity and proliferation.
- Novel expression of markers, including OLIG1, was observed in prostate tumors.
Conclusions:
- A unique genome-wide molecular signature for CD133+ and CD133- human prostate epithelial cells was established.
- This signature serves as a valuable resource for prostate stem cell research.
- The findings facilitate the identification of novel therapeutic targets for prostate cancer treatment.
